-
Je něco špatně v tomto záznamu ?
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
D. McLornan, DJ. Eikema, T. Czerw, N. Kröger, L. Koster, HC. Reinhardt, E. Angelucci, M. Robin, M. Bornhäuser, J. Passweg, A. Clark, J. Vydra, IE. Blau, R. Niittyvuopio, U. Platzbecker, JJ. Cornelissen, P. Chevallier, M. Srour, D. Stamatovic, J....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- nemoc štěpu proti hostiteli * MeSH
- primární myelofibróza * terapie MeSH
- příprava pacienta k transplantaci MeSH
- retrospektivní studie MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
We performed a retrospective assessment of patient- and transplant-specific characteristics and outcomes for 4142 patients undergoing allogeneic haematopoietic cell transplant for myelofibrosis between 1995 and 2018 across 278 centres. Activity increased steadily across the four analysed eras (<2006, 2006-2010, 2011-2014 and 2015-2018). Median recipient age increased over time between the earliest and most recent cohort (49.4 years (range, 20.1-68) versus 59.3 years (range, 18.1-78.1). Increasing number of patients with a Karnofsky performance status <90 underwent transplant over time. Increased utilisation of matched unrelated donors was apparent (<2006, 22.5% versus 2015-18, 45.2%; p < 0.001). Decreased use of myeloablative conditioning, increased use of busulphan-based platforms and anti-thymocyte globulin was evident. Of note, rates of acute (a)GVHD grade II-IV by day +100 decreased over time (p = 0.027) as did rates of chronic (c) GVHD, predominantly extensive cGVHD (<2006, 36% (31-41%) versus 2015-18, 23% (21-25%); p = 0.001). Overall, significant factors associated with worse overall survival and non-relapse mortality (NRM) remained older age, use of donors other than matched sibling, recipient CMV seropositivity and a lower Karnofsky performance status (<90). Multivariable analysis demonstrated improvements in overall survival and reductions in relapse risk over time with stable NRM rates despite increasing numbers of older, less fit patients and use of unrelated donors.
Centre Hospitalier Régional Universitaire de Lille Hospital Claude Huriez Huriez France
Charité Universitätsmedizin Berlin Berlin Germany
Department of Haematology and Stem Cell Transplant Beatson Centre Glasgow Scotland
Department of Haematology Erasmus MC Daniel den Hoed Cancer Center Rottrdam The Netherlands
Department of Haematology Military Medical Academy Belgrade Serbia
Department of Haematology St James Hospital Dublin Ireland
Department of Medical Statistics Leiden University Medical Centre Leiden The Netherlands
Division of Stem Cell Transplantation University Hospital Eppendorf Hamburg Germany
EBMT Data Office Leiden The Netherlands
Hematologia and Transplant Center IRCCS Ospedale Policlinico San Martino Genova Italy
Hôpital Saint Louis Service d'Hématologie Greffe Assistance Publique Hôpitaux de Paris Paris France
Hospital Clínico Universitario de Valencia Valencia Spain
Hospital Universitario 12 de Octubre Avd de Cordoba s n Madrid Spain
HUCH Comprehensive Cancer Center Helsinki Finland
Institute of Hematology and Blood Transfusion Prague Czech Republic
Klinik für Hämatologie Bereich Innere Medizin Universitätsspital Basel Basel Switzerland
Service des Maladies du Sang CHRU de Lille LIRIC INSERM U995 Universite de Lille Lille France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003785
- 003
- CZ-PrNML
- 005
- 20220127145851.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-021-01305-x $2 doi
- 035 __
- $a (PubMed)33911203
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a McLornan, D $u Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust and University College Hospital, London, UK. donal.mclornan@nhs.net
- 245 10
- $a Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis / $c D. McLornan, DJ. Eikema, T. Czerw, N. Kröger, L. Koster, HC. Reinhardt, E. Angelucci, M. Robin, M. Bornhäuser, J. Passweg, A. Clark, J. Vydra, IE. Blau, R. Niittyvuopio, U. Platzbecker, JJ. Cornelissen, P. Chevallier, M. Srour, D. Stamatovic, J. Martinez-Lopez, L. de Wreede, P. Hayden, JC. Hernández-Boluda, I. Yakoub-Agha
- 520 9_
- $a We performed a retrospective assessment of patient- and transplant-specific characteristics and outcomes for 4142 patients undergoing allogeneic haematopoietic cell transplant for myelofibrosis between 1995 and 2018 across 278 centres. Activity increased steadily across the four analysed eras (<2006, 2006-2010, 2011-2014 and 2015-2018). Median recipient age increased over time between the earliest and most recent cohort (49.4 years (range, 20.1-68) versus 59.3 years (range, 18.1-78.1). Increasing number of patients with a Karnofsky performance status <90 underwent transplant over time. Increased utilisation of matched unrelated donors was apparent (<2006, 22.5% versus 2015-18, 45.2%; p < 0.001). Decreased use of myeloablative conditioning, increased use of busulphan-based platforms and anti-thymocyte globulin was evident. Of note, rates of acute (a)GVHD grade II-IV by day +100 decreased over time (p = 0.027) as did rates of chronic (c) GVHD, predominantly extensive cGVHD (<2006, 36% (31-41%) versus 2015-18, 23% (21-25%); p = 0.001). Overall, significant factors associated with worse overall survival and non-relapse mortality (NRM) remained older age, use of donors other than matched sibling, recipient CMV seropositivity and a lower Karnofsky performance status (<90). Multivariable analysis demonstrated improvements in overall survival and reductions in relapse risk over time with stable NRM rates despite increasing numbers of older, less fit patients and use of unrelated donors.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a primární myelofibróza $x terapie $7 D055728
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a příprava pacienta k transplantaci $7 D019172
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Eikema, D J $u Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands
- 700 1_
- $a Czerw, T $u Maria Sklodowska-Curie Memorial Cencer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland
- 700 1_
- $a Kröger, N $u Division of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany
- 700 1_
- $a Koster, L $u EBMT Data Office, Leiden, The Netherlands
- 700 1_
- $a Reinhardt, Hans Christian $u Department of Hematology and Stem Cell Transplantation, West German Cancer Center University Hospital Essen, Essen, Germany
- 700 1_
- $a Angelucci, E $u Hematologia and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 700 1_
- $a Robin, M $u Hôpital Saint-Louis, Service d'Hématologie-Greffe, Assistance Publique Hôpitaux de Paris, Paris, France
- 700 1_
- $a Bornhäuser, M $u Universitaetsklinikum Dresden, Dresden, Germany
- 700 1_
- $a Passweg, J $u Klinik für Hämatologie,Bereich Innere Medizin, Universitätsspital Basel, Basel, Switzerland
- 700 1_
- $a Clark, A $u Department of Haematology and Stem Cell Transplant, Beatson Centre, Glasgow, Scotland
- 700 1_
- $a Vydra, J $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Blau, I E $u Charité Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Niittyvuopio, R $u HUCH Comprehensive Cancer Center, Helsinki, Finland
- 700 1_
- $a Platzbecker, U $u University Hospital Leipzig, Leipzig, Germany
- 700 1_
- $a Cornelissen, J J $u Department of Haematology, Erasmus MC/Daniel den Hoed Cancer Center, Rottrdam, The Netherlands
- 700 1_
- $a Chevallier, P $u CHU Nantes, Nantes, France
- 700 1_
- $a Srour, M $u Centre Hospitalier Régional Universitaire de Lille, Hospital Claude Huriez, Huriez, France
- 700 1_
- $a Stamatovic, D $u Department of Haematology, Military Medical Academy, Belgrade, Serbia
- 700 1_
- $a Martinez-Lopez, J $u Hospital Universitario 12 de Octubre, Avd de Cordoba s/n, Madrid, Spain
- 700 1_
- $a de Wreede, L $u Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands
- 700 1_
- $a Hayden, P $u Department of Haematology, St.James Hospital, Dublin, Ireland
- 700 1_
- $a Hernández-Boluda, J C $u Hospital Clínico Universitario de Valencia, Valencia, Spain
- 700 1_
- $a Yakoub-Agha, I $u Service des Maladies du Sang, CHRU de Lille, LIRIC, INSERM U995, Universite de Lille, Lille, France. ibrahim.yakoubagha@chru-lille.fr
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 9 (2021), s. 2160-2172
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33911203 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145847 $b ABA008
- 999 __
- $a ok $b bmc $g 1751290 $s 1154934
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 56 $c 9 $d 2160-2172 $e 20210428 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20220113
